Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Huw Thomas.

Newcastle AuthorsTitleYearFull text
Dr Emma Scott
Emily Archer Goode
Rebecca Garnham
Dr Kirsty Hodgson
Maggie Orozco Moreno
et al.
ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression2023
Dr Nahoum Anthony
Charlotte Jennings
Dr Mathew Martin
Dr Richard Noble
Nicole Phillips
et al.
Targeting cytotoxic agents through EGFR-mediated covalent binding and release2023
Dr Kirsty Hodgson
Maggie Orozco Moreno
Dr Emma Scott
Rebecca Garnham
Karen Livermore
et al.
The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer2023
Dr Emma Scott
Dr Kirsty Hodgson
Kat Cheung
Edward Yo
Laura Wilson
et al.
Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth2023
Dr Jill Hunter
Dr Jacqueline Butterworth
Helene Sellier
Dr Nicola Hannaway
Dr Saimir Luli
et al.
Mutation of the RelA(p65) Thr505 phosphosite disrupts the DNA replication stress response leading to CHK1 inhibitor resistance2022
Duncan Miller
Tristan Reuillon
Dr Lauren Molyneux
Dr Tim Blackburn
Dr Noel Edwards
et al.
Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor2022
Dr Richard Noble
Huw Thomas
Dr Yan Zhao
Professor Steve Wedge
Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma2022
Dr Marco Zaki
Dr Sari Alhasan
Dr Ruchi Shukla
Misti McCain
Maja Laszczewska
et al.
Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?2022
Dr Ian Hardcastle
Dr Ruth Bawn
Dr Tim Blackburn
Dr Celine Cano
Dr Sarah Cully
et al.
Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction2021
Alex Bainbridge
Dr Scott Walker
Joseph Smith
Yi Min Ng Ng
Huw Thomas
et al.
IKBKE activity enhances AR levels in advanced prostate cancer via modulation of the Hippo pathway2020
Liz Matheson
Huw Thomas
Marian Case
Dr Helen Blair
Rosanna Jackson
et al.
Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM2019
Stephanie Myers
Duncan Miller
Dr Lauren Molyneux
Dr Mercedeh Arasta
Dr Ruth Bawn
et al.
Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD42019
Dr Lindi Chen
Philip Berry
Dr Jennifer Bonner
Calum Kirk
Dr Katrina Wood
et al.
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma2019
Dr Catherine Willoughby
Huw Thomas
Dr Elaine Willmore
Suzanne Kyle
Dr Anita Wittner
et al.
Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy2019
Dr Dominic Jones
Laura Wilson
Huw Thomas
Dr Luke Gaughan
Dr Mark Wade
et al.
The histone demethylase enzymes KDM3A and KDM4B co-operatively regulate chromatin transactions of the estrogen receptor in breast cancer2019
Lucy Gentles
Dr Calum Kirk
Huw Thomas
Professor Steve Wedge
Professor Nicola Curtin
et al.
An investigation of the effect of tissue ischaemia upon DNA damage protein markers in ovarian cancer2017
Dr Aiste McCormick
Gavin Cuthbert
Dr Rachel O'Donnell
Dr Brian Wilson
Huw Thomas
et al.
Functional characterisation of a novel ovarian cancer cell line, NUOC-12017
Dr Richard Noble
Dr Natalie Bell
Dr Helen Blair
Huw Thomas
Nicole Phillips
et al.
Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma2017
Carlo Bawn
Dr Martin Galler
Huw Thomas
Suzanne Kyle
Professor Nicola Curtin
et al.
PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS2017
Dr Christopher Wong
Dr Ian Hardcastle
Christopher Matheson
Professor Herbie Newell
Dr Mangaleswaran Sivaprakasam
et al.
Structure-guided design of purine-based probes for selective Nek2 inhibition2017
Dr Gary Beale
Dr Emma Haagensen
Huw Thomas
Lan Wang
Charlotte Revill
et al.
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer2016
Dr Emma Haagensen
Huw Thomas
Dr Ross Maxwell
Professor Herbie Newell
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-0372016
Dr Emma Haagensen
Huw Thomas
Dr Ross Maxwell
Professor Herbie Newell
Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent2016
Dr Jill Hunter
Dr Jacqueline Butterworth
Helene Sellier
Huw Thomas
Dr Christopher Bacon
et al.
The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma2016
Liam Cornell
Dr Joanne Martin
Laura Ogle
Dr Catherine Willoughby
Dr Despina Televantou
et al.
DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival2015
Huw Thomas
Professor Nicola Curtin
Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself2015
Dr Johnny Roughan
Claire Coulter
Emeritus Professor Paul Flecknell
Huw Thomas
The Conditioned Place Preference Test for Assessing Welfare Consequences and Potential Refinements in a Mouse Bladder Cancer Model2014
James Murray
Huw Thomas
Philip Berry
Suzanne Kyle
Dr Miranda Patterson
et al.
Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules2014
Dr Frida Ponthan
Claire Whitworth
Huw Thomas
Dr Chris Redfern
Cell Survival Signalling through PPARδ and Arachidonic Acid Metabolites in Neuroblastoma2013
Christopher Hill
Dr David Jamieson
Huw Thomas
Dr Colin Brown
Professor Alan Boddy
et al.
Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo2013
Dr Emma Haagensen
Huw Thomas
Ian Wilson
Dr Suzannah Harnor
Sara Payne
et al.
The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice2013
Dr Anastasia Hepburn
Dr Stuart Williamson
Dr Amira El-Sherif
Dr Neha Sahay
Huw Thomas
et al.
Side Population in Human Non-Muscle Invasive Bladder Cancer Enriches for Cancer Stem Cells That Are Maintained by MAPK Signalling2012
Dr Emma Meczes
Huw Thomas
Professor Richard Edmondson
Professor Gareth Veal
Professor Alan Boddy
et al.
Therapy induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tumours2012
Huw Thomas
Professor Herbie Newell
Professor Nicola Curtin
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition2011
Dr Kappusamy Saravanan
Hannah Barlow
Marion Barton
Professor Hilary Calvert
Emeritus Professor Bernard Golding
et al.
Nucleoside Transport Inhibitors: Structure-Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of α1-Acid Glycoprotein2011
Tomasz Zaremba
Huw Thomas
Mike Cole
Dr Sally Coulthard
Professor Ruth Plummer
et al.
Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers2011
Huw Thomas
Dr Celine Roche
Dr Johanne Bentley
Dr Ian Hardcastle
Emeritus Professor Bernard Golding
et al.
Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU63012011
Huw Thomas
Suzanne Kyle
Ivanda Pavlovska
Professor Nicola Curtin
The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice2011
Dr Yvette Drew
Dr Evan Mulligan
Wan Vong
Huw Thomas
Suzanne Kyle
et al.
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA22011
Huw Thomas
Suzanne Kyle
Rafal Zur
Dr Evan Mulligan
Professor Nicola Curtin
et al.
6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance2010
Rachel Daniel
Dr Agata Rozanska
Dr Evan Mulligan
Dr Yvette Drew
Huw Thomas
et al.
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-0146992010
Tomasz Zaremba
Huw Thomas
Mike Cole
Professor Ruth Plummer
Professor Nicola Curtin
et al.
Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials2010
Dr Agata Rozanska
Dr Evan Mulligan
Huw Thomas
Deborah Castelbuono
Professor Deborah Tweddle
et al.
[abstract] Central nervous system (CNS) penetration, poly-ADP ribose polymerase (PARP) inhibition and enhancement of temozolomide activity against childhood medulloblastoma by AG-0146992009
Huw Thomas
Professor Nicola Curtin
Exploiting Homologous recombination repair defects in cancer cells2009
Dr Agata Rozanska
Huw Thomas
Dr Evan Mulligan
Dr Yvette Drew
Deborah Castelbuono
et al.
Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma2009
Huw Thomas
Dr Kappusamy Saravanan
Lan Wang
Mei Lin
Dr Julian Scott Northen
et al.
Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity2009
Dr Steven Darby
Huw Thomas
Professor Craig Robson
Professor Hing Leung
Dr Marie Mathers
et al.
Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease2009
Huw Thomas
Suzanne Kyle
Tim Robson
Professor Nicola Curtin
Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?2009
Professor Herbie Newell
Huw Thomas
Lan Wang
Dr Celine Roche
Dr Ian Hardcastle
et al.
[abstract] Preclinical in vitro and in vivo evaluation of the cyclin dependent kinase 2 inhibitor NU6102 and a water pro-drug NU63012008
Huw Thomas
Professor Nicola Curtin
Chemosensitisation by tricyclic poly(ADP-ribose) polymerase (PARP) inhibitors in vivo: More than just DNA repair? [abstract]2008
Suzanne Kyle
Huw Thomas
Dr Jane Mitchell
Professor Nicola Curtin
Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer2008
Huw Thomas
Gordon Taylor
Professor Herbie Newell
Professor Alan Boddy
An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed2007
Dr Jane Renwick
Gordon Taylor
Huw Thomas
Professor Alan Boddy
Dr Chris Redfern
et al.
Molecular targeting of retinoic acid metabolism in neuroblastoma: The role of the CYP26 inhibitor R116010 in vitro and in vivo2007
Professor Steven Clifford
Rachel Daniel
Dr Agata Rozanska
Huw Thomas
Professor Alan Boddy
et al.
Preclinical evaluation of the POLY-ADP ribose polymerase 1 (PARP-1) inhibitor AG014699 in combination with topotecan and temozolomide for the treatment of medulloblastoma and neuroblastoma2007
Huw Thomas
Dr Christopher Calabrese
Michael Batey
Suzanne Kyle
Professor Herbie Newell
et al.
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial2007
Professor Gareth Veal
Julie Errington
Huw Thomas
Professor Alan Boddy
Biliary excretion of etoposide in children with cancer2006
Huw Thomas
Dr Christopher Calabrese
Professor Herbie Newell
Lan Wang
Professor Nicola Curtin
et al.
Identification of a PARP inhibitor for clinical trial: Preclinical studies2006
Dr Yan Zhao
Huw Thomas
Michael Batey
Dr Ian Cowell
Professor Roger Griffin
et al.
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU74412006
Huw Thomas
Kathleen Parker
Suzanne Kyle
Professor Nicola Curtin
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase2005
Dr Christopher Calabrese
Michael Batey
Professor Alan Calvert
Professor barbara Durkacz
Suzanne Kyle
et al.
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG143612004
Dr Christopher Calabrese
Professor Nicola Curtin
Suzanne Kyle
Huw Thomas
Lan Wang
et al.
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase2004
Dr Christopher Calabrese
Michael Batey
Huw Thomas
Professor barbara Durkacz
Lan Wang
et al.
Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies2003
Huw Thomas
Gordon Taylor
Professor Herbie Newell
Professor Alan Boddy
Potentiation of raltitrexed (RTX) in vitro by thymidine phosphorylase (TP) and TP distribution in vivo2003
Dr Christopher Calabrese
Professor Nicola Curtin
Suzanne Kyle
Huw Thomas
Lan Wang
et al.
Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure2002
Huw Thomas
Mike Cole
Suzanne Elliott
Professor Herbie Newell
Professor Alan Calvert
et al.
Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide2002
Huw Thomas
Gordon Taylor
Professor Herbie Newell
Professor Alan Boddy
The in vivo distribution of a CEA directed antibody conjugated to thymidine phosphorylase2002
Professor Nicola Curtin
Dr Stephen Barton
Michael Batey
Dr Christopher Calabrese
Professor Alan Calvert
et al.
Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.2001
Gordon Taylor
Huw Thomas
Professor Herbie Newell
Professor Nicola Curtin
Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole2001
Peter Smith
Huw Thomas
Hannah Barlow
Professor Roger Griffin
Emeritus Professor Bernard Golding
et al.
In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity2001
Professor Alan Boddy
Melanie Griffin
Julieann Sludden
Huw Thomas
Kevin Fishwick
et al.
Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer2001
Peter Smith
Huw Thomas
Hannah Barlow
Professor Roger Griffin
Emeritus Professor Bernard Golding
et al.
In vitro activity and in vivo pharmacology of two novel nucleoside transport inhibitors, NU3108 and NU31212000
Dr Christopher Calabrese
Professor Nicola Curtin
Michael Batey
Huw Thomas
Suzanne Kyle
et al.
Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase2000
Professor Alan Boddy
Melanie Griffin
Julieann Sludden
Huw Thomas
Kevin Fishwick
et al.
Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer2000
Huw Thomas
Professor Alan Calvert
Professor Alan Boddy
Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours2000
Huw Thomas
Professor Alan Boddy
Professor Andrew Pearson
Professor Herbie Newell
Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial2000
Dr Christopher Calabrese
Huw Thomas
Alex White
Preclinical pharmacology of novel potent inhibitors of PARP1999
Dr Christopher Calabrese
Huw Thomas
Michael Batey
Professor Nicola Curtin
Professor Roger Griffin
et al.
Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase1999
Professor Gareth Veal
Professor Alan Boddy
Huw Thomas
Annie Parry
Professor Andrew Pearson
et al.
Real-time monitoring of carboplatin pharmacokinetics in paediatric patients receiving high dose chemotherapy1999
Professor Alan Boddy
Huw Thomas
High dose cyclosporin with etoposide - Toxicity and pharmacokinetic interaction in children with solid tumours1998
Huw Thomas
Professor Alan Boddy
Professor Andrew Pearson
Professor Herbie Newell
Validation of pharmacologically-guided dosing of carboplatin in paediatric patients1998
Professor Alan Boddy
Huw Thomas
Lynsey Robson
Professor Alan Calvert
A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer1997
Professor Alan Boddy
Huw Thomas
RMP-7. Potential as an adjuvant to the drug treatment of brain tumours1997
Professor Steve Wedge
Fiona Chapman
Gordon Taylor
Huw Thomas
Professor Alan Boddy
et al.
A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid1996
Professor Herbie Newell
Huw Thomas
Professor Alan Calvert
Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters1996
Professor Alan Boddy
Huw Thomas
Professor Herbie Newell
Professor Alan Calvert
Lynsey Robson
et al.
Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: A cancer research campaign phase I/II committee study1996
Professor Alan Calvert
Professor Alan Boddy
Dr Andrew Hughes
Lynsey Robson
Huw Thomas
et al.
Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.1995